+
Source: Sanoski CA, Bauman JL. The arrhythmias. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill. http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861§ionid=146057036. Accessed April 28, 2017.
++
++
++
Predominant mechanism is reentry, usually associated with organic heart disease causing atrial distention (eg, ischemia or infarction, hypertensive heart disease, valvular disorders).
++
Most common sustained arrhythmia.
Prevalence in United States, 0.4–1%; increases with age.
Prevalence expected to increase to 12–15 million Americans by 2050
Lifetime risk for AF in persons at least 40 years of age estimated to be 1 in 4
+++
CLINICAL PRESENTATION
++
+++
MEANS OF CONFIRMATION AND DIAGNOSIS
++
+++
DIFFERENTIAL DIAGNOSIS
++
Atrial flutter.
Atrial tachycardia.
Atrioventricular nodal reentry tachycardia (AVNRT)
Multifocal atrial tachycardia.
Paroxysmal supraventricular tachycardia.
Wolff-Parkinson-White syndrome.
++
+++
TREATMENT: GENERAL APPROACH
++
Evaluate need for acute treatment (usually with drugs that slow ventricular rate) (Fig. 1).
Consider methods to restore sinus rhythm, considering risks involved (eg, thromboembolism).
Consider ways to prevent long-term complications (eg, recurrent arrhythmia, thromboembolism).
++